FDA Approvals, Completed Tender Offers, Hospital Ratings, Trial Study Results, and Stock Price Movements - Research Report on Pfizer, Amgen, Cigna, Hologic, and Insys Therapeutics

NEW YORK, October 9, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Amgen, Inc. (NASDAQ: AMGN), Cigna Corporation (NYSE: CI), Hologic, Inc. (NASDAQ: HOLX), and Insys Therapeutics Inc. (NASDAQ: INSY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Pfizer Inc. Research Report

On October 3, 2013, Pfizer Inc. (Pfizer) announced that it has received U.S. Food and Drug Administration's (FDA) approval for DUAVEE^[TM] (conjugated estrogens/bazedoxifene) 0.45mg/20mg tablets, for the treatment of moderate-to-severe vasomotor symptoms associated with menopause and the prevention of postmenopausal osteoporosis. The Company stated that when the tablets are prescribed solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk and non-estrogen medication should be carefully considered. The Company reported that this approval of DUAVEE is the first in any country worldwide, and anticipates it to be available in the US in Q1 2014. The Full Research Report on Pfizer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/d702_PFE]

--

Amgen, Inc. Research Report

On October 1, 2013, Amgen, Inc. (Amgen) announced that the Company has completed its previously announced tender offer to purchase all outstanding shares of common stock of Onyx Pharmaceuticals Inc. (Onyx) for $125 per share in cash. The purchase price reported by the Company is $9.7 billion, net of estimated Onyx cash. Amgen informed that the tender offer expired at 12:00 midnight New York City Time on October 1, 2013. According to the depositary for the tender offer, approximately 57.7 million shares were validly tendered and not withdrawn in the tender offer, representing approximately 78.5% of Onyx's outstanding shares. Commenting on the acquisition, Robert A. Bradway, Chairman and CEO of Amgen, said, "We look forward to working together with the talented staff at Onyx to make the most of our exciting oncology portfolio and pipeline." The Full Research Report on Amgen, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/e96b_AMGN]

--

Cigna Corporation Research Report

On October 3, 2013, Cigna Corporation (Cigna) announced that it is adding Patient Experience ratings for hospitals across the country to its online physician and hospital directory. Cigna claims that the information is provided by the leading source of consumer information and recommendations, and includes results from millions of patient surveys. The Company further stated that the ratings include an overall patient rating that reflects consumers' overall rating of the hospital and if they would recommend the hospital to friends and family. The new patient experience ratings are available on myCigna.com to all its U.S. health plan customers. Commenting on the innovative step taken by the Company, Jackie Aube, Vice President of Product Development, Cigna, said, "For a number of years we've been a leader in providing our customers with reliable cost and quality information. Now we're improving the customer experience by adding patient reviews that include the aspects of care that are important to them." The Full Research Report on Cigna Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/7307_CI]

--

Hologic, Inc. Research Report

On October 2, 2013, Hologic, Inc. (Hologic) announced that the final analysis of the American Society of Breast Surgeons (ASBS) MammoSite Breast Brachytherapy Registry Trial data confirms previously noted "excellent" results and compares favorably with other forms of accelerated partial breast irradiation (APBI) and with outcomes seen in patients treated with whole breast irradiation with similar follow-up. The Company stated that the final analysis was published online before being printed in the August 22, 2013 issue of Annals of Surgical Oncology.Carter Houghton, Hologic's Senior Vice President and General Manager, Interventional Breast Solutions, said, "The acceptance of accelerated partial breast irradiation as an effective treatment option for women diagnosed with early stage breast cancer continues to grow worldwide due in part to the favorable results reported throughout this study. Hologic's MammoSite Radiation Therapy is a compassionate treatment option that allows women to return to their daily activities after just five days of treatment, as compared to the conventional five to seven weeks, while minimizing side effects such as skin burning and fatigue." The Full Research Report on Hologic, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/d132_HOLX]

--

Insys Therapeutics Inc. Research Report

On October 4, 2013, Insys Therapeutics Inc.'s (Insys Therapeutics) stock rose sharply by 7.29%, ending the day at $44.15. Over the previous three trading sessions, shares of Insys Therapeutics gained 20.99%, outperforming the Nasdaq Composite which declined 0.27% during the same period. The Full Research Report on Insys Therapeutics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/4c7f_INSY]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner